Abstract
Justification: The heterogeneous clinical outcomes observed in patients with advanced melanoma treated with immune checkpoint inhibitors highlight the need to identify predictive biomarkers of response. In this context, the BRAF gene emerges as a potential predictive biomarker due to its activating mutations found in approximately 50% of melanomas, which induce a tumor microenvironment di…